790 related articles for article (PubMed ID: 29858436)
21. Liver Disease: Nonalcoholic Fatty Liver Disease.
Cooper J; Baumgartner K; Smith A; St Louis J
FP Essent; 2021 Dec; 511():29-35. PubMed ID: 34855339
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
Alkhouri N; Feldstein AE
Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
[TBL] [Abstract][Full Text] [Related]
23. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
Harrison SA; Ratziu V; Boursier J; Francque S; Bedossa P; Majd Z; Cordonnier G; Sudrik FB; Darteil R; Liebe R; Magnanensi J; Hajji Y; Brozek J; Roudot A; Staels B; Hum DW; Megnien SJ; Hosmane S; Dam N; Chaumat P; Hanf R; Anstee QM; Sanyal AJ
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):970-985. PubMed ID: 32763196
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.
Hu KC; Wang HY; Liu SC; Liu CC; Hung CL; Bair MJ; Liu CJ; Wu MS; Shih SC
World J Gastroenterol; 2014 Jun; 20(24):7718-29. PubMed ID: 24976709
[TBL] [Abstract][Full Text] [Related]
25. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
Ooi GJ; Mgaieth S; Eslick GD; Burton PR; Kemp WW; Roberts SK; Brown WA
Obes Rev; 2018 Feb; 19(2):281-294. PubMed ID: 29119725
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
27. Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease.
Irvine KM; Okano S; Patel PJ; Horsfall LU; Williams S; Russell A; Powell EE
Sci Rep; 2021 Feb; 11(1):2858. PubMed ID: 33536476
[TBL] [Abstract][Full Text] [Related]
28. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
29. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.
Leoni S; Tovoli F; Napoli L; Serio I; Ferri S; Bolondi L
World J Gastroenterol; 2018 Aug; 24(30):3361-3373. PubMed ID: 30122876
[TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
Pallayova M; Taheri S
Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
[TBL] [Abstract][Full Text] [Related]
31. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of fibrosis tests in children with non-alcoholic fatty liver disease: A systematic review.
Draijer LG; van Oosterhout JPM; Vali Y; Zwetsloot S; van der Lee JH; van Etten-Jamaludin FS; Chegary M; Benninga MA; Koot BGP
Liver Int; 2021 Sep; 41(9):2087-2100. PubMed ID: 33894100
[TBL] [Abstract][Full Text] [Related]
33. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.
Kechagias S; Ekstedt M; Simonsson C; Nasr P
Hormones (Athens); 2022 Sep; 21(3):349-368. PubMed ID: 35661987
[TBL] [Abstract][Full Text] [Related]
34. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
35. Non-Alcoholic Fatty Liver Disease.
Brůha R
Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
[TBL] [Abstract][Full Text] [Related]
36. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.
Albhaisi S; Sanyal AJ
Pharmaceut Med; 2019 Dec; 33(6):451-463. PubMed ID: 31933238
[TBL] [Abstract][Full Text] [Related]
37. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
Zhu C; Zhou D; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
[TBL] [Abstract][Full Text] [Related]
38. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
39. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.
Lee BW; Lee YH; Park CY; Rhee EJ; Lee WY; Kim NH; Choi KM; Park KG; Choi YK; Cha BS; Lee DH;
Diabetes Metab J; 2020 Jun; 44(3):382-401. PubMed ID: 32431115
[TBL] [Abstract][Full Text] [Related]
40. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
